Endocrinology denials: appealing diabetes-drug, osteoporosis, and device denials

Denials in endocrinology center on GLP-1 receptor agonists and other diabetes drugs (step therapy and indication criteria), osteoporosis agents such as denosumab and romosozumab (step therapy and fracture-risk criteria), and diabetes devices (continuous glucose monitors and insulin pumps under specific coverage rules). Endocrine Society guidance supports these for the appropriate patients; the denial is generally a documentation gap mapped to the wrong place, not a coverage exclusion.

Why these denials happen

Plans require a documented trial of preferred or first-line agents before a GLP-1 or an osteoporosis biologic, plus the indication and severity criteria (for osteoporosis, the fracture-risk or bone-density thresholds). Diabetes devices follow their own coverage rules. The clinical case usually meets Endocrine Society guidance, so the denial fires when the prior-therapy trail or the qualifying criteria aren't mapped to the plan's policy.

The common denials

• GLP-1 or diabetes drug denied for step therapy or an off-label/indication question.
• Osteoporosis biologic (denosumab, romosozumab) denied — fracture-risk or step-therapy criteria not documented.
• Diabetes device (CGM, insulin pump) denied under its coverage rule (see the coverage guides).
• Non-preferred agent chosen without rationale over the plan's preferred drug.
• Reauthorization denied — continued response or necessity not re-documented.

Is it worth appealing?

How to appeal

1. 1

   Document the step trail

   Show the trial, failure, intolerance, or contraindication of the preferred or first-line agents the plan requires.

2. 2

   Establish the qualifying criteria

   For an osteoporosis biologic, document the fracture-risk or bone-density thresholds; for a diabetes drug, the indication the policy names.

3. 3

   For devices, follow the coverage rule

   Map a CGM or insulin-pump denial to its specific Medicare or commercial coverage criteria — the coverage guides break these down.

Frequently asked

Clinical-coverage patterns and guideline references are summarized for plain-language reference and vary by plan and payer policy. This is general information for clinicians and billing staff, not medical, legal, or coding advice — confirm against the governing coverage policy and the current guideline for each claim.